Logo image of AKUS

AKOUOS INC (AKUS) Stock Fundamental Analysis

NASDAQ:AKUS - Nasdaq - US00973J1016 - Common Stock - Currency: USD

13.29  +0.14 (+1.06%)

After market: 13.75 +0.46 (+3.46%)

Fundamental Rating

2

Taking everything into account, AKUS scores 2 out of 10 in our fundamental rating. AKUS was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AKUS as it has an excellent financial health rating, but there are worries on the profitability. AKUS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AKUS has reported negative net income.
In the past year AKUS has reported a negative cash flow from operations.
AKUS Yearly Net Income VS EBIT VS OCF VS FCFAKUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

AKUS has a Return On Assets (-41.06%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.06%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKUS Yearly ROA, ROE, ROICAKUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKUS Yearly Profit, Operating, Gross MarginsAKUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for AKUS has been increased compared to 1 year ago.
AKUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AKUS Yearly Shares OutstandingAKUS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M
AKUS Yearly Total Debt VS Total AssetsAKUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

AKUS has an Altman-Z score of 4.64. This indicates that AKUS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.64, AKUS is in the better half of the industry, outperforming 77.73% of the companies in the same industry.
There is no outstanding debt for AKUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.64
ROIC/WACCN/A
WACCN/A
AKUS Yearly LT Debt VS Equity VS FCFAKUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 17.30 indicates that AKUS has no problem at all paying its short term obligations.
AKUS has a Current ratio of 17.30. This is amongst the best in the industry. AKUS outperforms 88.63% of its industry peers.
AKUS has a Quick Ratio of 17.30. This indicates that AKUS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.30, AKUS belongs to the top of the industry, outperforming 88.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.3
Quick Ratio 17.3
AKUS Yearly Current Assets VS Current LiabilitesAKUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for AKUS have decreased strongly by -20.74% in the last year.
EPS 1Y (TTM)-20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -0.68% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.83%
EPS Next 2Y4.43%
EPS Next 3Y-2.59%
EPS Next 5Y-0.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKUS Yearly Revenue VS EstimatesAKUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
AKUS Yearly EPS VS EstimatesAKUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKUS Price Earnings VS Forward Price EarningsAKUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKUS Per share dataAKUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as AKUS's earnings are expected to decrease with -2.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.43%
EPS Next 3Y-2.59%

More info and screens

0

5. Dividend

5.1 Amount

AKUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOUOS INC

NASDAQ:AKUS (11/30/2022, 8:18:43 PM)

After market: 13.75 +0.46 (+3.46%)

13.29

+0.14 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)03-27 2023-03-27
Inst Owners0.04%
Inst Owner Change-73.85%
Ins Owners7.81%
Ins Owner Change0%
Market Cap491.01M
Analysts78.18
Price Target17.68 (33.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.37%
Min EPS beat(2)17.92%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)7.98%
Min EPS beat(4)-6.69%
Max EPS beat(4)24.81%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)3.07%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.72
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-2.62
EYN/A
EPS(NY)-2.29
Fwd EYN/A
FCF(TTM)-2.34
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS4.89
TBVpS4.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 428.37%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.3
Quick Ratio 17.3
Altman-Z 4.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)517.49%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.4%
EPS Next Y-8.83%
EPS Next 2Y4.43%
EPS Next 3Y-2.59%
EPS Next 5Y-0.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.45%
EBIT Next 3Y-23.94%
EBIT Next 5Y-5.41%
FCF growth 1Y-60.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.32%
OCF growth 3YN/A
OCF growth 5YN/A